In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Davunetide | Mixture Cerebrolysin | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Mixture | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 297 | 1,781 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 8 (7 in people) | 109 (96 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 5 | 41 · 9 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Davunetide | Cerebrolysin |
|---|---|---|
| NeuroprotectionNervous system and cognition | 11966548 | 661 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Cognition and memoryNervous system and cognition | 371423 | 26517293 |
|---|
| Exercise and physical functionNervous system and cognition | 1569 | 14610343 |
|---|
| Adverse eventsWhole body | 761 | 959041 |
|---|
| Receptor activity and mechanismWhole body | 893158 | 2232312377 |
|---|
| Immune responseImmune and inflammation | 44 | 3724310 |
|---|
| MortalityWhole body | 312 | 30228 |
|---|
| Inflammation markersImmune and inflammation | 413 | 508366 |
|---|
| Anxiety and moodMental health and mood | 514 | 261313 |
|---|
| Psychiatric symptomsMental health and mood | 11 | 99 |
|---|
| Mitochondrial functionNervous system and cognition | 44 | 1394 |
|---|
| SeizuresNervous system and cognition | 11 | 22 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 5 trials, ranked by phase, then posted results and enrollment: 3 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Allon Therapeutics313 participantsOct 2010 to Dec 2012
Progressive Supranuclear Palsy
University of California, Los Angeles63 participantsJul 2007 to Apr 2009
Schizophrenia
Allon Therapeutics234 participantsAug 2006 to Jun 2008
Mild Cognitive Impairment
Top 3 of 41 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ever Neuro Pharma GmbH242 participantsOct 2006 to Aug 2007
Vascular Dementia
Ever Neuro Pharma GmbH1,071 participantsSept 2006 to Feb 2011
Ischemic Stroke
Poznan University of Medical Sciences350 participants10 Jan 2023 to est. 31 Mar 2025
Acute Ischemic Stroke
2 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Davunetide | Cerebrolysin |
|---|---|---|
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in na | 11.8 NA PSPRS median change from baseline Placebo: 11.8 NA Dose studied: 30 mg twice daily52 weeksn = 3132014 | No comparable result 42 randomized-trial results measure it in another way or another unit. |
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in p value | No comparable result 9 randomized-trial results measure it in another way or another unit. | 0.02 p value ADAS-Cog comparison p value Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000 |
| NeuroprotectionNervous system and cognitionCompared as: difference from placebo, in points | No comparable result 4 randomized-trial results measure it in another way or another unit. | 2.085 points Difference in decreases 10-day cycles over 3 intervalsn not reported2025 |
| Inflammation markersNervous system and cognitionCompared as: value in the arm that got the peptide, in lesions | No randomized trial result 4 results from other study designs. | 14 lesions Gadolinium-positive lesion count Dose studied: 20 mln = 42016 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 12% Epistaxis Placebo: 8% Dose studied: 30 mg twice daily52 weeksn = 3122014 | |
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 4.3% Deaths Placebo: 8.7% Dose studied: 30 mL daily10 daysn = 462014 |
11.8 NA
PSPRS median change from baseline
Placebo: 11.8 NA
Dose studied: 30 mg twice daily52 weeksn = 3132014
No comparable result
42 randomized-trial results measure it in another way or another unit.
No comparable result
33 randomized-trial results measure it in another way or another unit.
No comparable result
9 randomized-trial results measure it in another way or another unit.
0.02 p value
ADAS-Cog comparison p value
Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000
No comparable result
4 randomized-trial results measure it in another way or another unit.
2.085 points
Difference in decreases
10-day cycles over 3 intervalsn not reported2025
No randomized trial result
4 results from other study designs.
14 lesions
Gadolinium-positive lesion count
Dose studied: 20 mln = 42016
12%
Epistaxis
Placebo: 8%
Dose studied: 30 mg twice daily52 weeksn = 3122014
No comparable result
33 randomized-trial results measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
4.3%
Deaths
Placebo: 8.7%
Dose studied: 30 mL daily10 daysn = 462014